Impact of tacrolimus versus cyclosporine in hepatitis C virus‐infected liver transplant recipients on recurrent hepatitis: A prospective, randomized trial
Paul Martin, Ronald W. Busuttil, Robert M. Goldstein, Jeffrey S. Crippin, Goran B. Klintmalm, William E. Fitzsimmons, Carol Uleman – 16 September 2004 – Hepatitis C virus (HCV)‐induced cirrhosis is the commonest indication for orthotopic liver transplantation, but HCV recurrence is nearly universal and may worsen patient / graft outcomes. The frequency and severity of HCV recurrence has apparently increased in recent years, raising concern about a possible role for newer immunosuppression regimens in this increase, including potentially tacrolimus.